Activation of the human complement cascade by bacterial cell walls, peptidoglycans, water-soluble peptidoglycan components, and synthetic muramylpeptides--studies on active components and structural requirements. 1987

A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
Department of Immunology, Center for Adult Diseases, Osaka.

Cell walls isolated from 29 strains of 24 gram-positive bacterial species, whose peptidoglycans belong to the group A type of Schleifer and Kandler's classification, with one exception (Arthrobacter sp.), were shown to activate the complement cascade in pooled fresh human serum mainly through the alternative pathway and partly through the classical one. The complement-activating effect of cell walls (5 species) possessing group B type peptidoglycan, except those of Corynebacterium insidiosum, was weaker than that of the walls with group A type peptidoglycan. Preparations of peptidoglycan isolated from cell walls of Staphylococcus aureus, Streptococcus pyogenes, and Lactobacillus plantarum also activated the alternative pathway of the complement cascade, but less effectively than the respective parent cell walls. A water-soluble "polymer" of peptidoglycan subunits (SEPS), which was prepared from Staphylococcus epidermidis peptidoglycans by treatment with a cross-bridge degrading endopeptidase, retained most of the complement-activating ability of the parent cell walls. A peptidoglycan "monomer," SEPS-M, which was obtained by hydrolysis of the glycan chain of SEPS with endo-N-acetylmuramidase to disaccharide units did not activate complement. In conformity with this finding, neither synthetic N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) nor MDP-L-Lys-D-Ala activated the complement cascade. Among several lipophilic derivatives of MDP, 6-O-(3-hydroxy-3-docosylhexacosanoyl)-MDP-L-Lys-D-Ala (BH48-MDP-L-Lys-D-Ala) and 6-O-(2-tetradecylhexadecanoyl)-MDP (B30-MDP) were shown to activate complement through the alternative as well as the classical pathway and exclusively through the classical pathway, respectively. The finding that a D-isoasparagine analog of B30-MDP caused the same effect as the parent molecule strongly suggests that the activation of complement by B30-MDP is different from that caused by cell wall peptidoglycans and a water-soluble "polymer" of peptidoglycan subunits.

UI MeSH Term Description Entries
D010457 Peptidoglycan A structural polymer of the bacterial cell envelope consisting of sugars and amino acids which is responsible for both shape determination and cellular integrity under osmotic stress in virtually all bacteria. Murein,Pseudomurein
D002240 Carbohydrate Sequence The sequence of carbohydrates within POLYSACCHARIDES; GLYCOPROTEINS; and GLYCOLIPIDS. Carbohydrate Sequences,Sequence, Carbohydrate,Sequences, Carbohydrate
D002473 Cell Wall The outermost layer of a cell in most PLANTS; BACTERIA; FUNGI; and ALGAE. The cell wall is usually a rigid structure that lies external to the CELL MEMBRANE, and provides a protective barrier against physical or chemical agents. Cell Walls,Wall, Cell,Walls, Cell
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000119 Acetylmuramyl-Alanyl-Isoglutamine Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity. Mur-NAc-L-Ala-D-isoGln,Muramyl Dipeptide,Acetylmuramyl Alanyl Isoglutamine,N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide,N-Acetylmuramyl-L-Alanyl-D-Isoglutamine,Alanyl Isoglutamine, Acetylmuramyl,Dipeptide, Muramyl,Isoglutamine, Acetylmuramyl Alanyl,Mur NAc L Ala D isoGln,N Acetyl Muramyl L Alanyl D Glutamic alpha Amide,N Acetylmuramyl L Alanyl D Isoglutamine
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
June 1982, [Osaka Daigaku shigaku zasshi] The journal of Osaka University Dental Society,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
January 1972, Postepy biochemii,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
January 1972, Postepy biochemii,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
January 1979, Ultramicroscopy,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
January 1976, International archives of allergy and applied immunology,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
July 1979, Infection and immunity,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
November 1992, Biochemical Society transactions,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
July 1982, Immunology,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
April 1987, Molecular immunology,
A Kawasaki, and H Takada, and S Kotani, and S Inai, and K Nagaki, and M Matsumoto, and K Yokogawa, and S Kawata, and S Kusumoto, and T Shiba
August 1983, Infection and immunity,
Copied contents to your clipboard!